Literature DB >> 11066047

Ovarian carcinoma diagnosis.

B A Goff1, L Mandel, H G Muntz, C H Melancon.   

Abstract

BACKGROUND: Ovarian carcinoma often is called the "silent killer" because the disease usually is not detected until an advanced stage. The authors' goal was to evaluate preoperative symptoms and factors that may contribute to delayed diagnosis for women with ovarian carcinoma.
METHODS: A two-page survey was distributed to 1500 women who subscribe to CONVERSATIONS!, a newsletter about ovarian carcinoma. Because the survey could be copied and given to other patients, 1725 surveys were returned from women in 46 states and 4 Canadian provinces.
RESULTS: The median age of the surveyed women was 52 years, and 70% had Stage III or IV disease (International Federation of Gynecology and Obstetrics). When asked about symptoms before the diagnosis of ovarian carcinoma, 95% reported symptoms, which were categorized as abdominal (77%), gastrointestinal (70%), pain (58%), constitutional (50%), urinary (34%), and pelvic (26%). Only 11% of women with Stage I/II and 3% with Stage III/IV reported no symptoms before their diagnosis. Women who ignored their symptoms were significantly more likely to be diagnosed with advanced disease compared with those who did not (P = 0.002). The time required for a health care provider to make the diagnosis was reported as less than 3 months by 55%, but greater than 6 months by 26% and greater than 1 year by 11%. Factors significantly associated with delay in diagnosis were omission of a pelvic exam at first visit; having a multitude of symptoms; being diagnosed initially with no problem, depression, stress, irritable bowel, or gastritis; not initially receiving an ultrasound, computed tomography, or CA 125 test; and younger age. The type of health care provider seen initially, insurance, and specific symptoms did not correlate with delayed diagnosis.
CONCLUSIONS: This large national survey confirms that the majority of women with ovarian carcinoma are symptomatic and frequently have delays in diagnosis. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 11066047     DOI: 10.1002/1097-0142(20001115)89:10<2068::aid-cncr6>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  123 in total

1.  A national initiative for women and healthcare providers: CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer campaign.

Authors:  Sun Hee Rim; Lindsey Polonec; Sherri L Stewart; Cynthia A Gelb
Journal:  J Womens Health (Larchmt)       Date:  2011-09-20       Impact factor: 2.681

2.  Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.

Authors:  Lori Brotto; Michael Brundage; Paul Hoskins; Ignace Vergote; Andres Cervantes; Herraez A Casado; A Poveda; Elizabeth Eisenhauer; Dongsheng Tu
Journal:  Support Care Cancer       Date:  2015-08-25       Impact factor: 3.603

3.  Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability.

Authors:  Barbara A Goff; Kimberly A Lowe; Jeannette C Kane; Marissa D Robertson; Marcia A Gaul; M Robyn Andersen
Journal:  Gynecol Oncol       Date:  2011-11-06       Impact factor: 5.482

Review 4.  The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.

Authors:  Anastasia Prodromidou; Panagiotis Andreakos; Charalampos Kazakos; Dimitrios Eftimios Vlachos; Despina Perrea; Vasilios Pergialiotis
Journal:  Inflamm Res       Date:  2017-03-04       Impact factor: 4.575

5.  A novel targeted therapy of Leydig and granulosa cell tumors through the luteinizing hormone receptor using a hecate-chorionic gonadotropin beta conjugate in transgenic mice.

Authors:  Gabriel Bodek; Susanna Vierre; Adolfo Rivero-Müller; Ilpo Huhtaniemi; Adam J Ziecik; Nafis A Rahman
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 6.  Contemporary progress in ovarian cancer screening.

Authors:  Christine S Walsh; B Y Karlan
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

7.  Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.

Authors:  Priya Samuel; Ryan Charles Pink; Daniel Paul Caley; James Michael Stevenson Currie; Susan Ann Brooks; David Raul Francisco Carter
Journal:  Tumour Biol       Date:  2015-09-19

8.  Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis.

Authors:  Zhanzhan Xu; Yu Zhou; Yexuan Cao; Thi Lan Anh Dinh; Jing Wan; Min Zhao
Journal:  Med Oncol       Date:  2016-10-18       Impact factor: 3.064

Review 9.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

Review 10.  Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies.

Authors:  Leo J Schouten; Christine Rivera; David J Hunter; Donna Spiegelman; Hans-Olov Adami; Alan Arslan; W Lawrence Beeson; Piet A van den Brandt; Julie E Buring; Aaron R Folsom; Gary E Fraser; Jo L Freudenheim; R Alexandra Goldbohm; Susan E Hankinson; James V Lacey; Michael Leitzmann; Annekatrin Lukanova; James R Marshall; Anthony B Miller; Alpa V Patel; Carmen Rodriguez; Thomas E Rohan; Julie A Ross; Alicja Wolk; Shumin M Zhang; Stephanie A Smith-Warner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04-01       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.